

31 October 2013

## TENDER RESULTS

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2012/13 Invitation to Tender, dated 31 October 2012.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

### Notification of Product Changes (NOPC) forms and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the **12<sup>th</sup> of the month prior to the date of subsidy change**. More information and NOPC forms can be found on our website – <http://www.pharmac.health.nz/medicines/how-medicines-are-funded/new-funding-applications/pharmaceutical-product-specifications-the-change-process>

Where a product does not have a current Pharmacode, suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand before the 12<sup>th</sup> of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

**2012/13 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2016**

**Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule**

1. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

<b>Chemical Name</b>	<b>Presentation; Pack size and type</b>	<b>Current subsidy and (price)</b>	<b>New subsidy and price</b>	<b>Sole supply brand (Supplier)</b>	<b>Date of listing/subsidy change for tender winning brand</b>	<b>Date of reference pricing of other listed brands</b>	<b>Sole Subsidised Supply date (and delisting of other listed brands)</b>	<b>Brand (Supplier) affected by reference pricing and delisting</b>
Pantoprazole	tab EC 20 mg; 100 tablet blister pack	\$1.23; 28 pack	\$2.68	Pantoprazole Actavis 20 (Actavis)	1 March 2014	1 May 2014	1 August 2014	Dr Reddy's Pantoprazole (Dr Reddy's)
Pantoprazole	tab EC 40 mg; 100 tablet blister pack	\$1.54; 28 pack	\$3.54	Pantoprazole Actavis 40 (Actavis)	1 March 2014	1 May 2014	1 August 2014	Dr Reddy's Pantoprazole (Dr Reddy's)
Fluoxetine hydrochloride	cap 20 mg; 90 cap blister pack	\$2.70; 84 pack	\$1.74	Arrow-Fluoxetine (Actavis)	1 February 2014	1 April 2014	1 July 2014	Fluox (Mylan)
Fluoxetine hydrochloride	tab dispersible 20 mg, scored; 30 tablet blister pack	\$2.50	\$2.50	Arrow-Fluoxetine (Actavis)	1 February 2014	1 April 2014	1 July 2014	Fluox (Mylan)

## Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of listing/price change for tender winning brand	Hospital Supply Status date (and delisting of other listed brands)	Brand (Supplier) to be delisted
Pantoprazole	tab EC 20 mg; 100 tablet blister pack	\$1.23; 28 pack	\$2.68	Pantoprazole Actavis 20 (Actavis)	1%	1 March 2014	1 May 2014	Dr Reddy's Pantoprazole (Dr Reddy's)
Pantoprazole	tab EC 40 mg; 100 tablet blister pack	\$1.54; 28 pack	\$3.54	Pantoprazole Actavis 40 (Actavis)	1%	1 March 2014	1 May 2014	Dr Reddy's Pantoprazole (Dr Reddy's)
Fluoxetine hydrochloride	cap 20 mg; 90 cap blister pack	\$2.70; 84 pack	\$1.74	Arrow-Fluoxetine (Actavis)	1%	1 February 2014	1 April 2014	Fluox (Mylan)
Fluoxetine hydrochloride	tab dispersible 20 mg, scored; 30 tablet blister pack	\$2.50	\$2.50	Arrow-Fluoxetine (Actavis)	1%	1 February 2014	1 April 2014	Fluox (Mylan)

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2011/12 Invitation to Tender dated 1 November 2011 and 2012/13 Invitation to Tender, dated 31 October 2012:

*2011/12 Invitation to tender*

Chemical Name	Line Item	Chemical Name	Line Item
Clonidine	TDDS 2.5mg, 100 mcg per day	Granisetron	Inj 1 mg
Clonidine	TDDS 5mg, 200 mcg per day	Travoprost	Eye drops 0.004%
Clonidine	TDDS 7.5mg, 300 mcg per day		

*2012/13 Invitation to tender*

Chemical Name	Line Item	Chemical Name	Line Item
Flecainide acetate	Cap long-acting 100 mg	Flecainide acetate	Tab 100 mg
Flecainide acetate	Cap long-acting 200 mg	Mitozantrone	inj 2 mg/ml, 12.5 ml
Flecainide acetate	Tab 50 mg	Sodium citro-tartrate	grans effervescent 4 g sachets

For products included in the 2011/12 Invitation to Tender or the 2012/13 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.